The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05339204

AML-21

Ages 18-59
All Genders

Study Summary

Depending on the variant of the disease, patients are divided into 3 groups: A, B and C. Group A include patients with acute myeloid leukemia (AML) inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, group B - AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1, AML with normal karyotype with or without gene mutations (FLT3, NPM1, CEBPa) regardless of the allele ratio, and also AML with cytogenetic abnormalities not classified as those within groups A/C, group C - AML with myelodysplasia-related changes. Patients from group A receive treatment according to the scheme: 2 courses "7+3", 2 courses "FLAG", then - 6 courses of maintenance therapy according to the scheme "5+5". Patients from group B are given one course of "7+3". After that, their minimal residual disease (MRD) status is assessed. In case MRD negativity is achieved after the 1st course of "7 +3", randomization is carried out: branch 1

therapy is similar to therapy for patients from group A (4 courses of induction and consolidation + 6 courses of maintenance chemotherapy (CT), allogeneic hematopoietic stem cell transplantation (allo-HSCT) is not planned), branch 2 - performing allo-HSCT should be done as soon as possible (before the start of maintenance CT is most desirable). If MRD negativity is not achieved after the 1st course of "7+3", the patient is given CT according to the standard program, followed by mandatory allo-HSCT. Patients from group C are treated either according to the "Aza-Ida-Ara-C" scheme, or according to the "Ven-DAC /AZA" scheme, followed by mandatory allo-HSCT.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Newly diagnosed, previously untreated AML;
Age from 18 to 59 years;
Somatic status - ECOG < 3.

Exclusion

Exclusion Criteria:

previous chemotherapy for AML;
pregnancy;
relapses and refractory forms of AML;
acute promyelocytic leukemia;
blast crisis of chronic myeloid leukemia;
de novo AML with t(9;22);
AML transformed from MDS or MPN after treatment, for which a different protocol isprovided;
Blastoid plasmacytoid dendritic cell neoplasia (with the exception of cases when asmall population of plasmacytoid dendritic progenitors is detected in the leukemicneoplasia).
Undifferentiated acute leukemia

Study Design

February 01, 2021

February 01, 2026

Study Description

"7+3" regimen:

    1. Cytarabine 200 mg/m2 (IV continuous infusion over 24 hours), days 1-7

    2. Daunorubicin 60 mg/m2 (IV bolus), days 1-3

  "FLAG" regimen:

    1. Fludarabine 25 mg/m2 (IV in 30 minutes), days 1-5

    2. Cytarabine 1500 mg/m2 (IV in 3 hours), days 1-5

    3. Granulocyte colony-stimulating factor 5 mcg/kg (subcutaneous injection), from day 6
       until regression of cytopenia

  "Aza-Ida-Ara-C" regimen:

    1. Azacitidine 75 mg/m2 (subcutaneous injection), days 1-3

    2. Idarubicin 3 mg/m2 (IV bolus), days 4-10

    3. Cytarabine 15 mg/m2 twice a day (subcutaneous injection), days 4-17

  "Ven-DAC/AZA"

    1. Venetoclax 400 mg once daily (PO), days 1-28

    2. Either Azacitidine or Decitabine Azacitidine 75 mg/m2 (subcutaneous injection), days 1-7
       Decitabine 20 mg/m2 (IV in 60 minutes). days 1-5

  "5+5" regimen

    1. Cytarabine 50 mg/m2 twice a day (subcutaneous injection), days 1-5

    2. Mercaptopurine 30 mg/m2 twice a day (PO), days 1-5

Connect with a study center

National Research Center for Hematology
Moscow,
Russian Federation
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.